Biologics work equally well for active Crohn's: head-to-head study

The first data comparing adalimumab and ustekinumab suggest similar efficacy and safety

Monotherapy with either adalimumab or ustekinumab appear to be equally effective in biologic-naïve patients with moderate to severe Crohn’s disease, a head-to-head analysis shows.

International researchers say their findings support the use of either monoclonal antibody as first-line treatment for affected patients and will aid clinical decision-making.

In the randomised active-comparator SEAVUE trial, the US-led team assigned 386 adults (mean age 37) with moderately to severely active Crohn’s disease and no prior